Linrodostat: all 22 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT03854032Phase 2Results posted
- A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCompletedNCT03792750Phase 1/2Results posted
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTerminatedNCT03695250Phase 1/2Results posted
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedNCT03519256Phase 2Results posted
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results posted
- An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCompletedNCT03329846Phase 3Results posted
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results posted
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
- Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentActive, not recruitingNCT04106414Phase 2
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04047706Phase 1
- A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
- A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy ParticipantsCompletedNCT03936374Phase 1
- An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT03417037Phase 3
- An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckWithdrawnNCT03386838Phase 3
- A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference TabletCompletedNCT03378310Phase 1
- A Study to Evaluate the Bioavailability of BMS-986205CompletedNCT03374228Phase 1
- A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a TabletCompletedNCT03362411Phase 1
- A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy SubjectsCompletedNCT03346837Phase 1
- An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy ParticipantsCompletedNCT03312426Phase 1
- Pharmacokinetics and Metabolism Study in Healthy Male ParticipantsCompletedNCT03247283Phase 1
- A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsCompletedNCT03192943Phase 1